(Q37396916)

20 August 2017

1 reference

title

First-line treatment of follicular lymphoma: a patient-oriented algorithm (English)

1 reference

20 August 2017

1 reference

1 reference

Kristin Feuerlein

1

1 reference

20 August 2017

Emanuele Zucca

series ordinal

2

1 reference

20 August 2017

Michele Ghielmini

series ordinal

3

1 reference

20 August 2017

publication date

1 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

50

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

325-334

1 reference

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Stem cell transplantation in follicular lymphoma: progress at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802713513

10.1080/10428190802713513

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference